RBE

RaySearch to present latest innovations in RayStation, RayCare and RayIntelligence at ISOP and NPC (NAPT)

Retrieved on: 
Thursday, April 4, 2024
Proton, NAPT, Conference, Proton therapy, Research, NPC, RBE, RaySearch Laboratories, Linear energy transfer, Future, National Association, LET, Medical imaging

STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.

Key Points: 
  • STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.
  • Visit us at RaySearch's table at ISOP and booth at NPC.
  • The focus during both ISOP and NPC will be on support for proton arcs and robust optimization based on linear energy transfer (LET) and adaptive therapy.
  • Marc Mlyn, President of RaySearch Americas, and David McPhail, VP of Sales for RaySearch Americas, will be present at the meetings and look forward to meeting existing and future clinical partners.

RaySearch to exhibit the latest software innovations for particle therapy at PTCOG 2022

Retrieved on: 
Monday, June 27, 2022
Transfer, Deep learning, Patient, Head, RaySearch Laboratories, FLASH, Linear energy transfer, RBE, LET, CBCT, Monte Carlo, GPU, News, ARC, Medical imaging

STOCKHOLM, June 27, 2022 /PRNewswire/ -- RaySearch Laboratories AB (publ) will exhibit at PTCOG 60 , to be held in Miami, Florida, USA, during June 27-July 1.

Key Points: 
  • STOCKHOLM, June 27, 2022 /PRNewswire/ -- RaySearch Laboratories AB (publ) will exhibit at PTCOG 60 , to be held in Miami, Florida, USA, during June 27-July 1.
  • The latest news in treatment planning system RayStation*, oncology information system RayCare*and oncology analytics system RayIntelligence will be on show.
  • RaySearch is a proud market leader in particle therapy planning and workflow software.
  • Robustness in proton arc treatments for head and neck cancer patients: impact of gantry angle spacing and number of revolutions

Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Wednesday, October 20, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Transfer, Safety, Ovarian cancer, Neutrophil, Depression, Radiation, Cell proliferation, Calcium carbonate, Association, Neoplasm, Survival, Colorectal cancer, Radionuclide, Human, Carboplatin, Alpha, LET, CI, Patient, Mouse, EANM, RBE, Becquerel, Linear energy transfer, Nuclear medicine, Cell, Ascites, Growth, Tissue, Peritoneal cavity, European Association of Urology, Half-life, PARP, PLD, Medical imaging, Platinum, Birth control, Pharmaceutical industry, Lithium

We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.

Key Points: 
  • We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.
  • Ovarian cancer mouse models were treated with 224Ra-CaCO3-MP (5 mg, 14-22 kBq/animal) one day following tumor cell inoculation.
  • When 224Ra-CaCO3-MP was administered in combination with carboplatin-PLD, survival was significantly prolonged compared to mice that received carboplatin-PLD alone.
  • Radspherin is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.